These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 27485270)

  • 1. Development of a scintillation proximity binding assay for high-throughput screening of hematopoietic prostaglandin D2 synthase.
    Meleza C; Thomasson B; Ramachandran C; O'Neill JW; Michelsen K; Lo MC
    Anal Biochem; 2016 Oct; 511():17-23. PubMed ID: 27485270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The discovery of quinoline-3-carboxamides as hematopoietic prostaglandin D synthase (H-PGDS) inhibitors.
    Deaton DN; Do Y; Holt J; Jeune MR; Kramer HF; Larkin AL; Orband-Miller LA; Peckham GE; Poole C; Price DJ; Schaller LT; Shen Y; Shewchuk LM; Stewart EL; Stuart JD; Thomson SA; Ward P; Wilson JW; Xu T; Guss JH; Musetti C; Rendina AR; Affleck K; Anders D; Hancock AP; Hobbs H; Hodgson ST; Hutchinson J; Leveridge MV; Nicholls H; Smith IED; Somers DO; Sneddon HF; Uddin S; Cleasby A; Mortenson PN; Richardson C; Saxty G
    Bioorg Med Chem; 2019 Apr; 27(8):1456-1478. PubMed ID: 30858025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substrate-induced product-release mechanism of lipocalin-type prostaglandin D synthase.
    Shimamoto S; Nakagawa Y; Hidaka Y; Maruno T; Kobayashi Y; Kawahara K; Yoshida T; Ohkubo T; Aritake K; Kaushik MK; Urade Y
    Biochem Biophys Res Commun; 2021 Sep; 569():66-71. PubMed ID: 34237429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of indole inhibitors of human hematopoietic prostaglandin D2 synthase (hH-PGDS).
    Edfeldt F; Evenäs J; Lepistö M; Ward A; Petersen J; Wissler L; Rohman M; Sivars U; Svensson K; Perry M; Feierberg I; Zhou XH; Hansson T; Narjes F
    Bioorg Med Chem Lett; 2015 Jun; 25(12):2496-500. PubMed ID: 25978964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NMR resonance assignments of mouse lipocalin-type prostaglandin D synthase/prostaglandin J
    Shimamoto S; Nakahata Y; Hidaka Y; Yoshida T; Ohkubo T
    Biomol NMR Assign; 2022 Oct; 16(2):225-229. PubMed ID: 35445291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical, functional, and pharmacological characterization of AT-56, an orally active and selective inhibitor of lipocalin-type prostaglandin D synthase.
    Irikura D; Aritake K; Nagata N; Maruyama T; Shimamoto S; Urade Y
    J Biol Chem; 2009 Mar; 284(12):7623-30. PubMed ID: 19131342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of hematopoietic prostaglandin D2 synthase (H-PGDS) by an alkaloid extract from Combretum molle.
    Moyo R; Chimponda T; Mukanganyama S
    BMC Complement Altern Med; 2014 Jul; 14():221. PubMed ID: 24996417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostaglandin synthase activity of sigma- and mu-class glutathione transferases in a parasitic trematode, Clonorchis sinensis.
    Kim J; Sohn WM; Bae YA
    Parasites Hosts Dis; 2024 May; 62(2):205-216. PubMed ID: 38835261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-quality crystals of human haematopoietic prostaglandin D synthase with novel inhibitors.
    Takahashi S; Tsurumura T; Aritake K; Furubayashi N; Sato M; Yamanaka M; Hirota E; Sano S; Kobayashi T; Tanaka T; Inaka K; Tanaka H; Urade Y
    Acta Crystallogr Sect F Struct Biol Cryst Commun; 2010 Jul; 66(Pt 7):846-50. PubMed ID: 20606289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipocalin-type and hematopoietic prostaglandin D synthases as a novel example of functional convergence.
    Urade Y; Eguchi N
    Prostaglandins Other Lipid Mediat; 2002 Aug; 68-69():375-82. PubMed ID: 12432930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hematopoietic prostaglandin D synthase inhibitors for the treatment of duchenne muscular dystrophy].
    Kamauchi S; Urade Y
    Brain Nerve; 2011 Nov; 63(11):1261-9. PubMed ID: 22068479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of the binding pocket of human hematopoietic prostaglandin (PG) D2 synthase (hH-PGDS): a tale of two waters.
    Trujillo JI; Kiefer JR; Huang W; Day JE; Moon J; Jerome GM; Bono CP; Kornmeier CM; Williams ML; Kuhn C; Rennie GR; Wynn TA; Carron CP; Thorarensen A
    Bioorg Med Chem Lett; 2012 Jun; 22(11):3795-9. PubMed ID: 22546671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and characterisation of new inhibitors for the human hematopoietic prostaglandin D2 synthase.
    Weber JE; Oakley AJ; Christ AN; Clark AG; Hayes JD; Hall R; Hume DA; Board PG; Smythe ML; Flanagan JU
    Eur J Med Chem; 2010 Feb; 45(2):447-54. PubMed ID: 19939518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. L-type prostaglandin D synthase regulates the trafficking of the PGD
    Binda C; Génier S; Degrandmaison J; Picard S; Fréchette L; Jean S; Marsault E; Parent JL
    J Biol Chem; 2019 Nov; 294(45):16865-16883. PubMed ID: 31575663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human hematopoietic prostaglandin D synthase inhibitor complex structures.
    Kado Y; Aritake K; Uodome N; Okano Y; Okazaki N; Matsumura H; Urade Y; Inoue T
    J Biochem; 2012 Apr; 151(4):447-55. PubMed ID: 22418579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dendritic cells express hematopoietic prostaglandin D synthase and function as a source of prostaglandin D2 in the skin.
    Shimura C; Satoh T; Igawa K; Aritake K; Urade Y; Nakamura M; Yokozeki H
    Am J Pathol; 2010 Jan; 176(1):227-37. PubMed ID: 20008150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel prostaglandin D synthase inhibitors generated by fragment-based drug design.
    Hohwy M; Spadola L; Lundquist B; Hawtin P; Dahmén J; Groth-Clausen I; Nilsson E; Persdotter S; von Wachenfeldt K; Folmer RH; Edman K
    J Med Chem; 2008 Apr; 51(7):2178-86. PubMed ID: 18341273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the L-PGDS-PGD2-DP1 receptor axis in sleep regulation and neurologic outcomes.
    Ahmad AS; Ottallah H; Maciel CB; Strickland M; Doré S
    Sleep; 2019 Jun; 42(6):. PubMed ID: 30893431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural and functional characterization of HQL-79, an orally selective inhibitor of human hematopoietic prostaglandin D synthase.
    Aritake K; Kado Y; Inoue T; Miyano M; Urade Y
    J Biol Chem; 2006 Jun; 281(22):15277-86. PubMed ID: 16547010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel amide and imidazole compounds as potent hematopoietic prostaglandin D
    Olson KL; Holt MC; Ciske FL; Kramer JB; Heiple PE; Collins ML; Johnson CM; Ho CS; Morano MI; Barrett SD
    Bioorg Med Chem Lett; 2021 Feb; 34():127759. PubMed ID: 33383152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.